AstraZeneca's combo lung disease therapy falls short of FDA approval
AstraZeneca's combo lung disease therapy falls short of FDA approval
Reuters: Health
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combo therapy to treat a form of lung disease, the drugmaker said on Tuesday.
Reuters: Health
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combo therapy to treat a form of lung disease, the drugmaker said on Tuesday.
Comments
Post a Comment